Proximal Humerus FracturesELEVATENCT07415889
Assessing the Functional Benefit of Structured Psychological Coaching in Mentally Vulnerable Patients With a Surgically Treated Proximal Humerus Fracture.
A study testing Psychological intervention in people with Proximal Humerus Fractures and Neuroticism, run by Zaandam Medical Center at 4 sites in Netherlands.
Trial summary
Although physical factors play an important role in the treatment and outcomes after proximal humerus fracture (PHF), psychosocial factors need to be taken into account as well. Few studies have been done to assess the influence of psychosocial factors and mental distress on the outcomes after shoulder surgery and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Proximal Humerus Fractures, Neuroticism
- What is being tested?
- Psychological intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 4 sitesNetherlands
- Study dates
- 2 Dec 2025to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Surgically treated proximal humerus fracture, not older than two weeks
- A high or very high level of neuroticism (cut-off score on NEO-FFI test off 37)
- Minimal age of 18 years
- The fracture must be a mono-injury (not part of a multi-injury incident)
Who cannot join
- Any diagnosed psychiatric disorder that is not adequately managed with medication.
- Not being able to communicate: language barrier, neurologic disorders
- Paralysis on the affected arm
- Not able to participate in online or real time psychological training
- Any other fracture besides the proximal humerus fracture in an upper extremity
- Head trauma with neurological symptoms
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands4 sites, 4 recruiting
- Recruiting
Amsterdam University Medical Center
Amsterdam
Charlotte M Lameijer, MD, PhD, +3120-5669111, c.lameijer@amsterdamumc.nl
- Not yet recruiting
OLVG
Amsterdam
Bas Twigt, MD, PhD, +31205108911, b.twigt@olvg.nl
- Not yet recruiting
Red Cross Hospital
Beverwijk
Maayke N van Sterkenburg, MD, PhD, +31251 265 555, mvansterkenburg@rkz.nl
- Recruiting
Zaandam Medical Center
Zaandam
Robert Jan Derksen, MD, PhD, MSc, +3175 650 2911, robertjan.derksen@zmc.nl
About this study
Although physical factors play an important role in the treatment and outcomes after proximal humerus fracture (PHF), psychosocial factors need to be taken into account as well.
Few studies have been done to assess the influence of psychosocial factors and mental distress on the outcomes after shoulder surgery and show that it has a negative correlation on the outcomes. It is reported that having low resilience, negative thoughts, signs of depression or anxiety have a significant negative relation with the patient reported outcomes (PROMs).
Read more
Mental vulnerability is linked to neuroticism, a personality factor of the Big Five traits, that can be characterized by the tendency to experience negative affect, especially when threatened, frustrated, or facing loss. Neuroticism is related to worse outcomes of health and disease in patients. Although studies have been done to objectify the correlation between psychological factors and functional outcomes after surgery there has not yet been a trial where an intervention has taken place to improve functional outcomes when patients have neurotic tendencies. With this study, we aim to improve the functional outcomes for patients with neuroticism and proximal humerus fractures undergoing surgery by giving them psychological training in the form of focused cognitive behavioral therapy additionally to the standard care. Psychological treatment has shown to improve the well-being of the 'patient characteristics associated with neuroticism and reduce rumination and worry.
Therefore, we hypothesize that providing psychological guidance, consisting of a focused cognitive behavioral therapy program, to patients with neuroticism after a PHF will lead to better patient related outcomes.
Read the detailed description
Introduction The primary objective of this study is to investigate whether psychological guidance, additionally to the standard care, given to patients with neuroticism that sustained a proximal humerus fracture, influences functional outcomes. The secondary objectives are to study if psychological guidance will lead to a better range of motion, lower pain levels, less use of pain medication, faster return to work, improvement in fear for movement, anxiety, depression, acceptance, self-efficacy, resilience, negative pain cognitions and better general health.
Methods This study is designed as a multicenter, prospective randomized controlled trial. Due to the nature of this study, it will be a single blinded study, the researchers will be blinded.
All patients with a PHF will be given information about the study via their physician and if they are eligible they are provided with the patient information form. The physician will notify the researcher and the researcher will call the patients to give more information about the study if needed and will ask for consent. Following consent neuroticism will be tested via the NEO-FFI. If patients score average or (very) low on neuroticism the patients will be thanked for filling in the questionnaire and will be told they are not eligible for the study. If patients score (very) high on neuroticism the researcher will ask the patient to participate. The researcher will give the patient up to seven days to consider participating in the study. After this period, the researcher will contact the patient again to obtain informed consent. If consent is given, another researcher will later randomize the patient into either the control group or the treatment group.
Intervention The control group will undergo the standard postoperative care consisting of multiple outpatient clinic visits with their surgeon where they will make additional radiographic pictures if needed and will look for early complications. Besides the visits with their surgeon the patients will have visits at 3, 6 and 12 months with a researcher or their surgeon. Besides the visits all the patients will be referred to a physical therapist. The intervention group will undergo the standard postoperative care and will additionally get psychological guidance given by licensed psychologists. The psychological guidance will consist of eight sessions over a duration of six months and starts two to three weeks after surgery.
Randomization and blinding When the patient provides informed consent, they will be randomly assigned (1:1) to the intervention (psychological training) group or the control group (standard follow up) using a web-based application with a computer-generated list. Participants are aware of allocation; masking is impossible because of the nature of the intervention. Investigators doing the follow up appointments are not aware of allocation. The investigator who will randomize the participants will be aware of allocation but will not take part in obtaining the data or the analysis of the data. We will employ an intention to treat analysis.
Sample size calculation Our sample size calculation was based on the CSS, as that is the most objective scoring system out of the OSS, CSS and qDASH, and a review, written by Buchbinder et al.l, on the different tools to measure shoulder function. They found a standard deviation of 17 and a minimally important change of 12 to detect a relevant difference between groups. With an alpha of 5% and power of 80%, 32 patients were needed per group. Taking into account an expected 10% loss of to follow up, inclusion of 35 patient per group was calculated and thus the aim was to include 70 patients in the total study.
Adverse events The sponsor will suspend the study if there is sufficient ground that continuation of the study will jeopardise subject health or safety. The sponsor will notify the accredited METC without undue delay of a temporary halt including the reason for such an action. The study will be suspended pending a further positive decision by the accredited METC. The investigator will take care that all subjects are kept informed.
(Serious) adverse events will be recorded from the start of the study until the end of the follow up period. If a life-threatening SAE is encountered, this study will be stopped immediately. The safety committee is then asked to perform and report an analysis of this SAE before the study will continue. The investigator will report all SAEs to the sponsor without undue delay after obtaining knowledge of the events, except for the following SAEs. The sponsor will report the SAEs through the web portal ToetsingOnline to the accredited METC that approved the protocol, within 7 days of first knowledge for SAEs that result in death or are life threatening followed by a period of maximum of 8 days to complete the initial preliminary report. All other SAEs will be reported within a period of maximum 15 days after the sponsor has first knowledge of the serious adverse events.
Statistical analysis The research data will be analysed using SPSS. A two sided p-value <0.05 indicates statistical significance. Differences between treatment groups will be assessed. The CSS, the VAS scores, rehabilitation time, time away from work, time not participating in normal daily activities, ROM, OSS and qDASH are continuous variables and will be presented as mean with SD (parametric) or median with quartiles (non-parametric) and compared using the Student's T-test (parametric) or Mann-Whitney U-test (non-parametric) according to the distribution of the data. The distribution of continuous data will be assessed visually inspecting histograms and boxplots. The MCID for the outcome measure will be used to determine the clinical relevance of the observed differences. To include all consecutive timepoints a linear mixed model will be constructed to assess the difference between the groups over all timepoints. The best covariance matrix over the timepoints will be assessed using the AIC and likelihood ratio. Included time points are 3, 6 and 12 months. The complications are categorical data and will be presented as number with frequencies and compared using the Chi-square test or Fisher's exact test, as applicable. For the psychological changes the analyses will be based on the intention-to-treat principle. Linear mixed model (LMM) analyses were conducted through a marginal model to evaluate the difference in secondary outcomes between the intervention group and control group.
Quality assurance and monitoring Quality assurance will be done via the study monitoring office of the Amsterdam university medical center. Every site will get one visit during the duration of the study.
Data will be verified and compared to external data sources such as the medical records and the paper filled in questionnaires.
- Conditions
- Proximal Humerus Fractures, Neuroticism
- Being tested
- Psychological intervention
- Keywords
- Neuroticism, Proximal humerus fracture, Shoulder, Cognitive behavioral therapy, Surgery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psychological interventionBehavioural
Psychological guidance consists of 8 sessions cognitive behavior therapy and starts three weeks after surgery. Sessions consist of psychoeducation and evidence-based interventions and exercises concerning gradual activation relaxation techniques, pain perception and coping with pain, changing unhelpful beliefs, fear, worry about pain and revalidation. Improving treatment adherence (physiotherapy, medication, psychological treatment) and (perceived) social support. Treatment will be guided by licensed medical psychologists. The first 3 sessions will be at the hospital outpatient clinic of the psychologists and the other 5 sessions will be either via videocall or at the outpatient clinic, by patients' choice. The sessions will last 45-60 minutes. There is no use of comparator or placebo.
| Study group | Role | What they receive |
|---|---|---|
| Control arm | No intervention | Standard care is administered to these participants. Standard care consisting of a surgical treatment of the proximal humerus fracture, painkillers, multiple outpatient clinic visits during recovery and a referral to an physical therapist. |
| Psychological intervention arm | Active comparator | Psychological guidance consisting of 8 sessions with a licensed psychologist. The participants in this group will also get standard care. Receives: Behavioral: Psychological intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional outcome score - Constant Shoulder Score
The Constant Shoulder Score (CSS) is a comprehensive questionnaire that evaluates shoulder function across four domains: pain, activities of daily living (ADLs), range of motion (ROM), and strength. Pain and ADLs are self-reported by the patient, while ROM and strength are assessed by an investigator. Strength is measured at a 90-degree lateral abduction angle. The CSS consists of 10 items, with a separate assessment for each arm, providing a detailed measure of shoulder function. Lowest score is 0 and highest score is 100. A higher score indicates a better function.
Measured: The score will be tested at 3, 6 and 12 months after surgery.
Secondary outcomes (9)
Functional outcome core - Oxford Shoulder Score
The Oxford Shoulder Score (OSS) is a self-assessment questionnaire consisting of 12 items, designed to evaluate two main domains: pain and daily shoulder function. Four of the questions focus on pain, while the remaining eight assess daily functional limitations. The recall period for this questionnaire is 4 weeks. Scores ranging from 0 to 48, with lower scores indicating better function.
Measured: The score will be tested at 3, 6 and 12 months after surgery.
Functional outcome score - quick Disability of the Arm, Shoulder and Hand
The Quick Disability of the Arm, Shoulder, and Hand (qDASH) is a shortened version of the original DASH questionnaire, comprising 11 items in total. It assesses two key domains: symptoms and shoulder function. Of the 11 questions, three pertain to symptoms, and eight focus on functional limitations. The recall period for the qDASH is 1 week. Scale for this scores ranges from 0 to 100. Lower scores indicate better function.
Measured: The score will be tested at 3, 6 and 12 months after surgery.
Pain levels using Visual Analogue Scale
The Visual Analogue Scale (VAS) consists of a 10 cm line with two extremes: 'no pain' at one end and 'worst possible pain' at the other. The patient marks their perceived level of pain on the scale, and the pain intensity is quantified by measuring the distance from the 'no pain' endpoint to the marked point.
Measured: The score will be tested at 3, 6 and 12 months after surgery.
Complications after surgery
infection, hardware failure, nonunion, malunions, secondary dislocation, AVN, mortality
Measured: The outcome will be tested at 3, 6 and 12 months after surgery.
Range of motion
The shoulder's range of motion will be measured using a goniometer. The measurements will include forward flexion, abduction, extension, and both internal and external rotation.
Measured: The outcome will be tested at 3, 6 and 12 months after surgery
Psychological change - Movement anxiety
Anxiety will be assessed using the Tampa Scale for Kinesophobia. This questionnaire consists of 17 items. A higher scores indicates a higher movement anxiety.
Measured: The changes will be measured at 6 months after surgery.
Psychological change - Resilience
Resilience is measured using the Brief Resilience Scale. This questionnaire consist of 6 items. A higher score indicates more resilience and a better ability to bounce back from stress and adversity.
Measured: The changes will be measured at 6 months after surgery.
Psychological change - Anxiety and depression
The Hospital Anxiety and Depression questionnaire is used to measure the changes in anxiety and depression. The questionnaire consists of 14 items, 7 for depression and 7 for anxiety. A higher scores indicates more severe symptoms.
Measured: The changes will be measured at 3,6 and 12 months after surgery.
General Health
General Health is measured using the 36-Item Short Form Health Survey. Scores for this questionnaire range from 0 to 100. A higher score indicates a better general health status.
Measured: This score is measured at 3,6 and 12 months after surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start2 Dec 2025
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Proximal Humerus FracturesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a randomized controlled trial (RCT) with two arms, where patients are randomly assigned to either the intervention group or the control group. The intervention group receives the intended treatment, while the control group receives standard care. Patients cannot switch between groups during the study. The patients are not blinded during the study.
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zaandam Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Amsterdam University Medical Center, OLVG, Red Cross Hospital Beverwijk
- Responsible party
- Principal investigator, Robert Jan Derksen, Zaandam Medical Center
- Investigators
- Robert Jan Derksen, MD, PhD, MSc, Principal investigator, Zaandam Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07415889
- Sponsor's protocol ID
- ELEVATE study
- Acronym
- ELEVATE
- Status last verified
- Feb 2026
- First submitted
- 10 Jan 2026
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Functional Benefit of Structured Psychological Coaching in Mentally Vulnerable Patients With a Surgically Treated Proximal Humerus Fracture.
- ClinicalTrials.gov ID
- NCT07415889
- Acronym / sponsor ID
- ELEVATE / ELEVATE study
- Conditions
- Proximal Humerus Fractures, Neuroticism
- Keywords
- Neuroticism, Proximal humerus fracture, Shoulder, Cognitive behavioral therapy, Surgery
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Zaandam Medical CenterUniversity, hospital or other
- Collaborators
- Amsterdam University Medical Center, OLVG, Red Cross Hospital Beverwijk
- Study start
- 2 Dec 2025 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although physical factors play an important role in the treatment and outcomes after proximal humerus fracture (PHF), psychosocial factors need to be taken into account as well.
Few studies have been done to assess the influence of psychosocial factors and mental distress on the outcomes after shoulder surgery and show that it has a negative correlation on the outcomes. It is reported that having low resilience, negative thoughts, signs of depression or anxiety have a significant negative relation with the patient reported outcomes (PROMs).
Mental vulnerability is linked to neuroticism, a personality factor of the Big Five traits, that can be characterized by the tendency to experience negative affect, especially when threatened, frustrated, or facing loss. Neuroticism is related to worse outcomes of health and disease in patients. Although studies have been done to objectify the correlation between psychological factors and functional outcomes after surgery there has not yet been a trial where an intervention has taken place to improve functional outcomes when patients have neurotic tendencies. With this study, we aim to improve the functional outcomes for patients with neuroticism and proximal humerus fractures undergoing surgery by giving them psychological training in the form of focused cognitive behavioral therapy additionally to the standard care. Psychological treatment has shown to improve the well-being of the 'patient characteristics associated with neuroticism and reduce rumination and worry.
Therefore, we hypothesize that providing psychological guidance, consisting of a focused cognitive behavioral therapy program, to patients with neuroticism after a PHF will lead to better patient related outcomes.
Detailed description
Introduction The primary objective of this study is to investigate whether psychological guidance, additionally to the standard care, given to patients with neuroticism that sustained a proximal humerus fracture, influences functional outcomes. The secondary objectives are to study if psychological guidance will lead to a better range of motion, lower pain levels, less use of pain medication, faster return to work, improvement in fear for movement, anxiety, depression, acceptance, self-efficacy, resilience, negative pain cognitions and better general health.
Methods This study is designed as a multicenter, prospective randomized controlled trial. Due to the nature of this study, it will be a single blinded study, the researchers will be blinded.
All patients with a PHF will be given information about the study via their physician and if they are eligible they are provided with the patient information form. The physician will notify the researcher and the researcher will call the patients to give more information about the study if needed and will ask for consent. Following consent neuroticism will be tested via the NEO-FFI. If patients score average or (very) low on neuroticism the patients will be thanked for filling in the questionnaire and will be told they are not eligible for the study. If patients score (very) high on neuroticism the researcher will ask the patient to participate. The researcher will give the patient up to seven days to consider participating in the study. After this period, the researcher will contact the patient again to obtain informed consent. If consent is given, another researcher will later randomize the patient into either the control group or the treatment group.
Intervention The control group will undergo the standard postoperative care consisting of multiple outpatient clinic visits with their surgeon where they will make additional radiographic pictures if needed and will look for early complications. Besides the visits with their surgeon the patients will have visits at 3, 6 and 12 months with a researcher or their surgeon. Besides the visits all the patients will be referred to a physical therapist. The intervention group will undergo the standard postoperative care and will additionally get psychological guidance given by licensed psychologists. The psychological guidance will consist of eight sessions over a duration of six months and starts two to three weeks after surgery.
Randomization and blinding When the patient provides informed consent, they will be randomly assigned (1:1) to the intervention (psychological training) group or the control group (standard follow up) using a web-based application with a computer-generated list. Participants are aware of allocation; masking is impossible because of the nature of the intervention. Investigators doing the follow up appointments are not aware of allocation. The investigator who will randomize the participants will be aware of allocation but will not take part in obtaining the data or the analysis of the data. We will employ an intention to treat analysis.
Sample size calculation Our sample size calculation was based on the CSS, as that is the most objective scoring system out of the OSS, CSS and qDASH, and a review, written by Buchbinder et al.l, on the different tools to measure shoulder function. They found a standard deviation of 17 and a minimally important change of 12 to detect a relevant difference between groups. With an alpha of 5% and power of 80%, 32 patients were needed per group. Taking into account an expected 10% loss of to follow up, inclusion of 35 patient per group was calculated and thus the aim was to include 70 patients in the total study.
Adverse events The sponsor will suspend the study if there is sufficient ground that continuation of the study will jeopardise subject health or safety. The sponsor will notify the accredited METC without undue delay of a temporary halt including the reason for such an action. The study will be suspended pending a further positive decision by the accredited METC. The investigator will take care that all subjects are kept informed.
(Serious) adverse events will be recorded from the start of the study until the end of the follow up period. If a life-threatening SAE is encountered, this study will be stopped immediately. The safety committee is then asked to perform and report an analysis of this SAE before the study will continue. The investigator will report all SAEs to the sponsor without undue delay after obtaining knowledge of the events, except for the following SAEs. The sponsor will report the SAEs through the web portal ToetsingOnline to the accredited METC that approved the protocol, within 7 days of first knowledge for SAEs that result in death or are life threatening followed by a period of maximum of 8 days to complete the initial preliminary report. All other SAEs will be reported within a period of maximum 15 days after the sponsor has first knowledge of the serious adverse events.
Statistical analysis The research data will be analysed using SPSS. A two sided p-value <0.05 indicates statistical significance. Differences between treatment groups will be assessed. The CSS, the VAS scores, rehabilitation time, time away from work, time not participating in normal daily activities, ROM, OSS and qDASH are continuous variables and will be presented as mean with SD (parametric) or median with quartiles (non-parametric) and compared using the Student's T-test (parametric) or Mann-Whitney U-test (non-parametric) according to the distribution of the data. The distribution of continuous data will be assessed visually inspecting histograms and boxplots. The MCID for the outcome measure will be used to determine the clinical relevance of the observed differences. To include all consecutive timepoints a linear mixed model will be constructed to assess the difference between the groups over all timepoints. The best covariance matrix over the timepoints will be assessed using the AIC and likelihood ratio. Included time points are 3, 6 and 12 months. The complications are categorical data and will be presented as number with frequencies and compared using the Chi-square test or Fisher's exact test, as applicable. For the psychological changes the analyses will be based on the intention-to-treat principle. Linear mixed model (LMM) analyses were conducted through a marginal model to evaluate the difference in secondary outcomes between the intervention group and control group.
Quality assurance and monitoring Quality assurance will be done via the study monitoring office of the Amsterdam university medical center. Every site will get one visit during the duration of the study.
Data will be verified and compared to external data sources such as the medical records and the paper filled in questionnaires.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- This study is a randomized controlled trial (RCT) with two arms, where patients are randomly assigned to either the intervention group or the control group. The intervention group receives the intended treatment, while the control group receives standard care. Patients cannot switch between groups during the study. The patients are not blinded during the study.
| Arm | Type | Receives |
|---|---|---|
| Control arm | No intervention | –Standard care is administered to these participants. Standard care consisting of a surgical treatment of the proximal humerus fracture, painkillers, multiple outpatient clinic visits during recovery and a referral to an physical therapist. |
| Psychological intervention arm | Active comparator | Behavioral: Psychological interventionPsychological guidance consisting of 8 sessions with a licensed psychologist. The participants in this group will also get standard care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Surgically treated proximal humerus fracture, not older than two weeks
- A high or very high level of neuroticism (cut-off score on NEO-FFI test off 37)
- Minimal age of 18 years
- The fracture must be a mono-injury (not part of a multi-injury incident)
Key exclusion criteria (6 listed)
- Any diagnosed psychiatric disorder that is not adequately managed with medication.
- Not being able to communicate: language barrier, neurologic disorders
- Paralysis on the affected arm
- Not able to participate in online or real time psychological training
- Any other fracture besides the proximal humerus fracture in an upper extremity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psychological interventionPsychological guidance consists of 8 sessions cognitive behavior therapy and starts three weeks after surgery. Sessions consist of psychoeducation and evidence-based interventions and exercises concerning gradual activation relaxation techniques, pain perception and coping with pain, changing unhelpful beliefs, fear, worry about pain and revalidation. Improving treatment adherence (physiotherapy, medication, psychological treatment) and (perceived) social support. Treatment will be guided by licensed medical psychologists. The first 3 sessions will be at the hospital outpatient clinic of the psychologists and the other 5 sessions will be either via videocall or at the outpatient clinic, by patients' choice. The sessions will last 45-60 minutes. There is no use of comparator or placebo. | Behavioural | Psychological intervention arm |
Primary outcome
Functional outcome score - Constant Shoulder Score
Time frame: The score will be tested at 3, 6 and 12 months after surgery.
The Constant Shoulder Score (CSS) is a comprehensive questionnaire that evaluates shoulder function across four domains: pain, activities of daily living (ADLs), range of motion (ROM), and strength. Pain and ADLs are self-reported by the patient, while ROM and strength are assessed by an investigator. Strength is measured at a 90-degree lateral abduction angle. The CSS consists of 10 items, with a separate assessment for each arm, providing a detailed measure of shoulder function. Lowest score is 0 and highest score is 100. A higher score indicates a better function.
9 secondary outcomes
Functional outcome core - Oxford Shoulder Score
Time frame: The score will be tested at 3, 6 and 12 months after surgery.
Functional outcome score - quick Disability of the Arm, Shoulder and Hand
Time frame: The score will be tested at 3, 6 and 12 months after surgery.
Pain levels using Visual Analogue Scale
Time frame: The score will be tested at 3, 6 and 12 months after surgery.
Complications after surgery
Time frame: The outcome will be tested at 3, 6 and 12 months after surgery.
Range of motion
Time frame: The outcome will be tested at 3, 6 and 12 months after surgery
Psychological change - Movement anxiety
Time frame: The changes will be measured at 6 months after surgery.
Psychological change - Resilience
Time frame: The changes will be measured at 6 months after surgery.
Psychological change - Anxiety and depression
Time frame: The changes will be measured at 3,6 and 12 months after surgery.
General Health
Time frame: This score is measured at 3,6 and 12 months after surgery.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Proximal Humerus Fractures
RecruitingObservational study
Duration of Immobilization After Reverse Total Arthroplasty for Proximal Humerus Fractures
Proximal Humeral Fracture, Reverse Total Shoulder Arthroplasty
Not yet recruiting
Magnesium Alloy Scaffold With Controlled Degradation for Periarticular Bone Defects
Periarticular Bone Defect, Proximal Humerus Fracture
Not yet recruiting
Study on Outcomes of Proximal Humerus Fractures
Proximal Humerus Fracture
Not yet recruiting
X-BS Ortho Bone Graft Study
Orthopedic Disorder, Trauma Injury
RecruitingObservational study
Exactech Proximal Humerus Fracture Plate System Post Market Clinical Follow-up
Proximal Humeral Fracture, Fracture Dislocation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Robert Jan Derksen, MD, PhD, MSc principal investigator
Zaandam Medical Center
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Psychological intervention in people with Proximal Humerus Fractures and Neuroticism, run by Zaandam Medical Center at 4 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Denise E de Gruijter, MD (+3175 650 7474, d.e.degruijter@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional outcome score - Constant Shoulder Score (time frame: The score will be tested at 3, 6 and 12 months after surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.